Description: Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Home Page: www.oramed.com
1185 Avenue of the Americas
New York,
NY
10036
United States
Phone:
844 967 2633
Officers
| Name | Title |
|---|---|
| Mr. Nadav Kidron Esq. | President, CEO & Executive Chairman |
| Dr. Miriam Kidron Ph.D. | Chief Scientific Officer & Director |
| Mr. Avraham Gabay | CFO, Treasurer & Secretary |
| Mr. Joshua Hexter | Chief Operating & Business Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 22.87 |
| Price-to-Book MRQ: | 0.6238 |
| Price-to-Sales TTM: | 129.0002 |
| IPO Date: | |
| Fiscal Year End: | August |
| Full Time Employees: | 0 |